Skip to main content

Table 3 The clinicopathologic characteristics of the patients of no progression group and progression group

From: Is hysterectomy beneficial in radical cystectomy for female patient with urothelial carcinoma of bladder? A retrospective analysis of consecutive 112 cases from a single institution

 

No-progression (n = 86)

Progression (n = 26)

p

Age (yr)

69.00 (61.00–76.00)

70.50 (63.75–78.00)

0.370b

BMI (kg/m2)

23.0 (21.2–26.3)

24.6 (22.3–27.0)

0.100b

ORC

65 (75.6%)

19 (73.1%)

0.796c

LRC

21 (24.4%)

7 (26.9%)

 

Location of the tumor

  

0.777c

 Posterior wall or trigone

62 (72.1%)

18 (69.2%)

 

 Other location

24 (27.9%)

8 (30.8%)

 

Pathologic stage

  

0.159c

 Ta and Tis and T1

25 (29.1%)

3 (11.5%)

 

 T2

31 (36.0%)

10 (38.5%)

 

 T3 and T4

30 (34.9%)

13 (50.0%)

 

Pathologic nodal stage

  

0.006c

 N0

79 (91.9%)

18 (69.2%)

 

 N+

7 (8.1%)

8 (30.8%)

 

Negative margin

83 (96.5%)

24 (92.3%)

0.329c

Positive margin

3 (3.5%)

2 (7.7%)

 

No neoadjuvant/adjuvant chemotherapy

79 (91.9%)

17 (65.4%)

0.002c

Neoadjuvant/adjuvant chemotherapy

7 (8.1%)

9 (34.6%)

 
  1. BMI Body Mass Index, ASA American Society of Anesthesiologists, ORC open radical cystectomy, LRC laparoscopic radical cystectomy, aIndependent-Samples T test, bMann-Whitney U test, cχ2 test (or Fisher’s exact test)